H.R. 2197, introduced in March 2025, would prohibit hospitals and other healthcare providers participating in the 340B drug program from using their pharmaceutical savings to pay for gender-affirming medical care for transgender patients. The 340B program allows covered entities to purchase certain drugs at discounted prices, and providers typically use the savings to support their broader operations and patient services. This bill would specifically bar those savings from being used to cover sex reassignment surgeries and hormone therapies for transgender individuals. The legislation does not establish new funding requirements or timelines, but rather restricts how existing program savings can be allocated. The bill would affect any hospital, safety-net clinic, or other healthcare provider that participates in the 340B program and currently offers transgender medical services.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.